A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas
Latest Information Update: 28 Jan 2026
At a glance
- Drugs Icotrokinra (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms ICONIC-TOTAL
- Sponsors Janssen Research & Development; Janssen-Cilag
Most Recent Events
- 20 Jan 2026 Planned End Date changed from 10 Jun 2027 to 17 Feb 2027.
- 24 Oct 2025 According to Johnson & Johnson Media Release, Edward (Ted) Lain, MD, MBA Executive Director of the Austin Institute for Clinical Research in Austin, Texas, and study investigator.
- 24 Oct 2025 Results presented in the Johnson & Johnson Media Release.